Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BuccaGLP
- Development stage
- Preclinical
- Lead developer
- Insu Therapeutics
- Modality
- Peptides
- Administration
- Buccal
01
Overview
BuccaGLP is an investigational, needle-free buccal formulation of semaglutide being developed by Insu Therapeutics, a spin-off from the University of British Columbia. The formulation utilizes a mucoadhesive, layered dosage-form architecture designed to adhere to the inner cheek (buccal mucosa) and direct the unidirectional release of semaglutide particles toward the underlying tissue, facilitating absorption directly into the bloodstream and avoiding gastrointestinal degradation. BuccaGLP is being developed as a potential non-invasive, needle-free alternative to injectable GLP-1 receptor agonists for the treatment of metabolic diseases, including type 2 diabetes and obesity.
- Other names
- BuccaGLPbuccal semaglutide
02
Targets
Beyond the preview
Go deeper on BuccaGLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BuccaGLP.